Talking about the next generation: What’s beyond the leading edge of biotech and pharma?

A flood of interest in Alzheimer’s research. A flurry of action in AI-enabled drug discovery. Payers coming to grips with pricey cell and gene therapies. And a cadre of drugmakers looking to go carbon-neutral as DEI measures come to the fore. We’ll delve into all these subjects and more...